Background: Hypertrophic cardiomyopathy (HCM) is a complex disease partly explained by
the effects of individual gene variants on sarcomeric protein biomechanics. At the cellular …

Cardiac myosin binding protein-C (cMyBP-C) is a structural and regulatory component of
cardiac thick filaments. It is observed in electron micrographs as seven to nine transverse …

Hypertrophic cardiomyopathy (HCM) is the most common inherited form of heart disease,
associated with over 1,000 mutations, many in β-cardiac myosin (MYH7). Molecular studies of …

Hypertrophic cardiomyopathy (HCM) is a heritable cardiovascular disorder that affects 1 in
500 people. A significant percentage of HCM is attributed to mutations in β-cardiac myosin, …

Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are a powerful
platform for uncovering disease mechanisms and assessing drugs for efficacy/toxicity. …

Hypertrophic cardiomyopathy (HCM) affects 1 in 500 people and leads to hyper-contractility
of the heart. Nearly 40 percent of HCM-causing mutations are found in human β-cardiac …

Combined pulmonary insufficiency (PI) and stenosis (PS) is a common long-term sequela
after repair of many forms of congenital heart disease, causing progressive right ventricular (…

BACKGROUND: Modulating myosin function is a novel therapeutic approach in patients with
cardiomyopathy. Danicamtiv is a novel myosin activator with promising preclinical data that …

We sought to establish a large animal model of inherited hypertrophic cardiomyopathy (HCM)
with sufficient disease severity and early penetrance for identification of novel therapeutic …

Background: In patients with complex congenital heart disease, such as those with tetralogy
of Fallot, the right ventricle (RV) is subject to pressure overload stress, leading to RV …